aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
OncoPrecision, founded with a mission to revolutionize cancer treatment, focuses on developing advanced technologies that replicate cancer patients' diseases ex-vivo. This allows for rapid and accurate testing of a wide range of treatments simultaneously. Their core vision is to enable oncologists to provide the most suitable treatment for each patient while assisting pharmaceutical companies in developing transformational therapies. The company targets the oncology market, aiming to enhance personalized cancer treatment and accelerate the creation of innovative therapies.
Notable affiliated individuals and investors include leading oncologists and biotech investors committed to advancing cancer care. OncoPrecision has achieved significant milestones in developing its proprietary ex-vivo testing platform, garnering attention for its potential to personalize and improve cancer treatment outcomes. The company's impact lies in its ability to streamline the treatment selection process for oncologists and expedite the development of new cancer therapies, positioning itself as a pivotal player in the oncology sector.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Cancer Treatment
Technology
AI, Biotech
Tags
Biotech, Healthtech
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Pharmaceutical
Geographic Exposure
United States
When was OncoPrecision founded?
OncoPrecision was founded in 2020.
Where is OncoPrecision’s headquarters located?
OncoPrecision’s headquarters is located in Córdoba, AR.
When was OncoPrecision’s last funding round?
OncoPrecision’s most recent funding round was for $3.3M (USD) in August 2022.
How many employees does OncoPrecision have?
OncoPrecision has 37 employees as of Feb 4, 2024.
How much has OncoPrecision raised to-date?
As of July 05, 2023, OncoPrecision has raised a total of $4.2M (USD) since Aug 1, 2022.
Add Comparison
Total Raised to Date
$4.2M
USD
Last Update Aug 1, 2022
Last Deal Details
$3.3M
USD
Aug 1, 2022
Seed
Total Employees Over Time
37
As of Feb 2024
OncoPrecision Address
Córdoba,
Córdoba Province
Argentina
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts